Pasar al contenido principal

ESTUDIO DE LA REGULACION DE LAS VIAS DE SEÑALIZACION DEPENDIENTES DE STING POR LAS PROTEINAS PARP-1 Y PARP-2 EN CANCER

PID2023-146049OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO INSTITUT HOSPITAL DEL MAR D'INVESTIGACIONS MEDIQUES

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity

  • Martínez Bosch, Neus
  • Manero Rupérez, Noemí
  • Vázquez-Bellón, Núria
  • Nickell-Hernández, Bennett
  • Ventura-Blanch, Cristina
  • Lutfi, Nura
  • Lechuga, Carmen G.
  • Martínez, Carlos
  • Moreno, Mireia
  • Ampurdanés, Coral
  • Abad Cortel, Etna
  • Iglesias Coma, Mar
  • Muñoz-Escribano, María
  • Janic, Ana
  • Rovira, Meritxell
  • Guerra, Carmen
  • Rabinovich, Gabriel A.
  • Yélamos López, José
  • Navarro, Pilar
Pancreatic cancer represents one of the most lethal tumors, characterized by an immunosuppressive microenvironment and a lack of cytotoxic immune cell infiltrates, which confer resistance to immunotherapy. Here, we demonstrate that deletion of poly(ADP-ribose) polymerase 2 (PARP2) in a Myc-driven mouse model of pancreatic cancer delays tumor progression and increases survival. Mechanistically, PARP2 loss induces enrichment of pathways associated with genomic instability and replicative stress, leading to increased γH2AX, chromosomal instability, and micronuclei accumulation. In addition to these tumor-intrinsic effects, PARP2 deletion reshapes the tumor microenvironment, promoting infiltration of cytotoxic T and natural killer cells while reducing immunosuppressive cell populations, enhancing antitumor cytotoxicity. These findings are recapitulated in a KrasG12D-driven orthotopic pancreatic ductal adenocarcinoma model. Collectively, our data support selective PARP2 inhibition as a promising therapeutic strategy for pancreatic cancer by impairing genome integrity and boosting antitumor immune response, thereby opening potential avenues for combating this devastating disease., This work was supported by the following grants: Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) grants PI20/00625 and PI23/00591 (P.N.); Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) grant PI19/00514 (C.G.); Carmen Delgado/Miguel Pérez Mateo Grants-Asociación Cancer de Páncreas and Asociación Española de Pancreatología (P.N., C.G., and J.Y.); Spanish Ministry of Science, Innovation, and Universities (MICIU/AEI /10.13039/501100011033, co-funded by the European Union) grant PID2023-146049OB-I00 (J.Y.); Spanish Ministry of Science, Innovation, and Universities (MICIU) grant PID2021-127710OB-I00 (A.J.); Spanish Ministry of Science, Innovation, and Universities (MICIU) grant PID2022-136973OB-I00 (M.R.); Cancer Research Innovation in Science (CRIS) Cancer Foundation (Excellence Grant) (M.R.); Ramón y Cajal Research Fellowship grant RYC2018-025244-I (A.J.); Ministerio de Ciencia, Tecnología e Innovación (Redes Federales de Alto Impacto) (G.A.R.); and Sales and Baron Foundations (G.A.R.).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Prognostic value of PARP1 and PARP2 copy number alterations in prostate cancer

  • Segalés Tañà, Laura, 1994-
  • Bellmunt Molins, Joaquim, 1959-
  • Perera Bel, Júlia
  • Vargas-Parra, Gardenia
  • Juanpere, Nuria
  • Lopez-Segura, David
  • Rodriguez-Vida, Alejo
  • Colomo Saperas, Luis Alberto
  • Cecchini Rosell, Lluís
  • Lloreta, Josep, 1958-
  • Yélamos López, José
  • Fumadó Ciutat, Lluis
  • Hernández Llodrà, Silvia
PARP1/2 have overlapping yet nonredundant biological functions in DNA repair and androgen receptor-transcriptional regulation. Studies on PARP alterations in human tumors have yielded conflicting results. In prostate cancer (PCa), PARP1/2 protein overexpression has been related to androgen deprivation therapy resistance, biochemical recurrence, and progression to metastases. PARP inhibitors have been approved for treating metastatic castration-resistant PCa with homologous recombination repair gene mutations. However, the significance of PARP1/2 genomic alterations is not fully studied. We aimed to analyze PARP1/2 alterations in PCa, assess their value as prognostic markers, and explore their relevance for potential therapeutic stratification. PARP1/2 copy number status was evaluated in 121 PCa primary tumors using real-time PCR. In 29 of them, a regional pelvic lymph node involvement was also analyzed. BRCA1/2 somatic mutations were analyzed in 24 PCa cases. Relationship with clinicopathological features, progression to metastases, and prostate-specific antigen recurrence was assessed. PARP1 loss and PARP2 gain were detected in 34.7% and 32.2% of primary tumors, respectively, with a high frequency of co-occurrence (P < .001). Both alterations were statistically associated with locally advanced disease at the time of diagnosis (P = .036; P = .006), metastatic dissemination (P = .014; P = .003), and other aggressive clinicopathological characteristics (such as the presence of Gleason pattern 5, high-grade, and high-stage). Cases with exclusive PARP2 gain had the shortest time to prostate-specific antigen recurrence, whereas double wt patients displayed the best outcome (P = .007). In 29 paired primary tumors and regional pelvic lymph node involvement, PARP1 loss showed strong concordance (P = .001), whereas PARP2 gain did not (P = .411). In conclusion, loss of PARP1 and gain of PARP2 show strong co-occurrence and are associated with clinicopathological characteristics of aggressiveness. PARP2 alterations appear to have a particularly significant impact on disease prognosis. Furthermore, these data suggest that the analysis of PARP1/2 copy number status could be useful in predicting PCa outcomes. Its role in therapy warrants further evaluation., The study has been funded with the “BecaLeonardo de la Peña 2022” through the Foundation for Research in Urology of the Spanish Association of Urology, and the FIS/ISC III/FEDER PI22/00171 from the Spanish Ministry of Health. Yélamos lab is funded by grant PID2023-146049OB-I00 from Agencia Estatal de Investigación of Spanish Ministry of Science, Innovation and Universities (MICIU/AEI /10.13039/501100011033 and FEDER, UE).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Prognostic value of PARP1 and PARP2 copy number alterations in prostate cancer

  • Segalés Tañà, Laura, 1994-
  • Bellmunt Molins, Joaquim, 1959-
  • Perera Bel, Júlia
  • Vargas-Parra, Gardenia
  • Juanpere, Nuria
  • Lopez-Segura, David
  • Rodriguez-Vida, Alejo
  • Colomo Saperas, Luis Alberto
  • Cecchini Rosell, Lluís
  • Lloreta, Josep, 1958-
  • Yélamos López, José
  • Fumadó Ciutat, Lluis
  • Hernández Llodrà, Silvia
PARP1/2 have overlapping yet nonredundant biological functions in DNA repair and androgen receptor-transcriptional regulation. Studies on PARP alterations in human tumors have yielded conflicting results. In prostate cancer (PCa), PARP1/2 protein overexpression has been related to androgen deprivation therapy resistance, biochemical recurrence, and progression to metastases. PARP inhibitors have been approved for treating metastatic castration-resistant PCa with homologous recombination repair gene mutations. However, the significance of PARP1/2 genomic alterations is not fully studied. We aimed to analyze PARP1/2 alterations in PCa, assess their value as prognostic markers, and explore their relevance for potential therapeutic stratification. PARP1/2 copy number status was evaluated in 121 PCa primary tumors using real-time PCR. In 29 of them, a regional pelvic lymph node involvement was also analyzed. BRCA1/2 somatic mutations were analyzed in 24 PCa cases. Relationship with clinicopathological features, progression to metastases, and prostate-specific antigen recurrence was assessed. PARP1 loss and PARP2 gain were detected in 34.7% and 32.2% of primary tumors, respectively, with a high frequency of co-occurrence (P < .001). Both alterations were statistically associated with locally advanced disease at the time of diagnosis (P = .036; P = .006), metastatic dissemination (P = .014; P = .003), and other aggressive clinicopathological characteristics (such as the presence of Gleason pattern 5, high-grade, and high-stage). Cases with exclusive PARP2 gain had the shortest time to prostate-specific antigen recurrence, whereas double wt patients displayed the best outcome (P = .007). In 29 paired primary tumors and regional pelvic lymph node involvement, PARP1 loss showed strong concordance (P = .001), whereas PARP2 gain did not (P = .411). In conclusion, loss of PARP1 and gain of PARP2 show strong co-occurrence and are associated with clinicopathological characteristics of aggressiveness. PARP2 alterations appear to have a particularly significant impact on disease prognosis. Furthermore, these data suggest that the analysis of PARP1/2 copy number status could be useful in predicting PCa outcomes. Its role in therapy warrants further evaluation., The study has been funded with the “BecaLeonardo de la Peña 2022” through the Foundation for Research in Urology of the Spanish Association of Urology, and the FIS/ISC III/FEDER PI22/00171 from the Spanish Ministry of Health. Yélamos lab is funded by grant PID2023-146049OB-I00 from Agencia Estatal de Investigación of Spanish Ministry of Science, Innovation and Universities (MICIU/AEI /10.13039/501100011033 and FEDER, UE).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity

  • Martínez Bosch, Neus
  • Manero Rupérez, Noemí
  • Vázquez-Bellón, Núria
  • Nickell-Hernández, Bennett
  • Ventura-Blanch, Cristina
  • Lutfi, Nura
  • Lechuga, Carmen G.
  • Martínez, Carlos
  • Moreno, Mireia
  • Ampurdanés, Coral
  • Abad Cortel, Etna
  • Iglesias Coma, Mar
  • Muñoz-Escribano, María
  • Janic, Ana
  • Rovira, Meritxell
  • Guerra, Carmen
  • Rabinovich, Gabriel A.
  • Yélamos López, José
  • Navarro, Pilar
Pancreatic cancer represents one of the most lethal tumors, characterized by an immunosuppressive microenvironment and a lack of cytotoxic immune cell infiltrates, which confer resistance to immunotherapy. Here, we demonstrate that deletion of poly(ADP-ribose) polymerase 2 (PARP2) in a Myc-driven mouse model of pancreatic cancer delays tumor progression and increases survival. Mechanistically, PARP2 loss induces enrichment of pathways associated with genomic instability and replicative stress, leading to increased γH2AX, chromosomal instability, and micronuclei accumulation. In addition to these tumor-intrinsic effects, PARP2 deletion reshapes the tumor microenvironment, promoting infiltration of cytotoxic T and natural killer cells while reducing immunosuppressive cell populations, enhancing antitumor cytotoxicity. These findings are recapitulated in a KrasG12D-driven orthotopic pancreatic ductal adenocarcinoma model. Collectively, our data support selective PARP2 inhibition as a promising therapeutic strategy for pancreatic cancer by impairing genome integrity and boosting antitumor immune response, thereby opening potential avenues for combating this devastating disease., This work was supported by the following grants: Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) grants PI20/00625 and PI23/00591 (P.N.); Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) grant PI19/00514 (C.G.); Carmen Delgado/Miguel Pérez Mateo Grants-Asociación Cancer de Páncreas and Asociación Española de Pancreatología (P.N., C.G., and J.Y.); Spanish Ministry of Science, Innovation, and Universities (MICIU/AEI /10.13039/501100011033, co-funded by the European Union) grant PID2023-146049OB-I00 (J.Y.); Spanish Ministry of Science, Innovation, and Universities (MICIU) grant PID2021-127710OB-I00 (A.J.); Spanish Ministry of Science, Innovation, and Universities (MICIU) grant PID2022-136973OB-I00 (M.R.); Cancer Research Innovation in Science (CRIS) Cancer Foundation (Excellence Grant) (M.R.); Ramón y Cajal Research Fellowship grant RYC2018-025244-I (A.J.); Ministerio de Ciencia, Tecnología e Innovación (Redes Federales de Alto Impacto) (G.A.R.); and Sales and Baron Foundations (G.A.R.).